Report Publication Announcement • Oct 25, 2021
Report Publication Announcement
Open in ViewerOpens in native device viewer
Xspray Pharma (publ) announces that the company is bringing forward the publication of its interim report for January-September, 2021, to Tuesday, October 26, 2021, instead of on Friday, November 4, 2021, as previously announced.
The work with the quarterly accounts has proceeded faster than expected, therefore the Q3 interim report will be released earlier than previous communicated.
Per Andersson, CEO, Xspray Pharma AB Phone: +46 (0) 706 88 23 48 E-mail: [email protected]
Xspray Pharma AB (publ) is a pharma company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.
The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today's original drugs before the secondary patents expire. Xspray's goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 68 in the beginning of 2021. The company's leading product candidates, HyNap-Dasa, HyNap-Nilo, and HyNap-Sora, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Tasigna® (nilotinib) and Nexavar® (sorafenib). HyNap-Dasa is being developed as an improved version of Sprycel. HyNap-Nilo is being developed as an improved version of Tasigna and has has received orphan drug status from the US FDA. HyNap-Sora is being developed as an improved version of Nexavar®.
The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). www.xspraypharma.com
Xspray Pharma brings forward publication of the Q3 interim report
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.